Navigation Links
Stonegate Report About Unigene Laboratories Inc.
Date:3/13/2008

therapies address the reduction of pain and the suppression of inflammation; however, no disease modifying therapeutic is available for OA. In addition to a well-established body of evidence regarding calcitonin's effect on bone resorption, both in vivo and in vitro clinical studies suggest that calcitonin may have chondroprotective qualities (counter the acceleration of cartilage degradation), while at the same time, mitigating pain. With 21 million people suffering from this disease in the U.S. alone and with no curative treatment available, a positive outcome in this trial could open an enormous opportunity for Unigene.

Long-term positive industry outlook in the osteoporosis market - The majority of Unigene's pipeline is focused on finding a more efficient delivery of current products that address the osteoporosis market. The osteoporosis market is poised for solid growth over the long-term. Datamonitor has valued the market at $8.7 billion in 2007. Fueled by pipeline products and an aging population, the market is projected to increase to $11.1 billion by 2016. The osteoporosis market is experiencing significant change that can be described as transitional rather than revolutionary. Products that improve bioavailability, tolerability and/or provide more efficient and convenient delivery methods of current drugs are projected to be significant growth drivers in this market over the next ten years. Successful products will have the potential of producing blockbuster revenues. Unigene is positioned at the heart of this high-growth segment of the osteoporosis market.

Safety concerns could dramatically increase sales of calcitonin-based products - Bisphosphonate therapies and selective estrogen receptor modulators (SERMS) are the current market leaders in the osteoporosis market; however, both therapies have been associated with serious side effects. Since 2003, medical journal articles have suggested that long-term use of bisphosphonates could lead to
'/>"/>

SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Helix BioPharma reports Q2 2008 highlights, financial results
5. Oncothyreon reports full year and fourth quarter 2007 financial results
6. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 AstraZeneca (NYSE: ... Virginia (UVa) in Charlottesville, today announced that ... collaboration to enhance development of new treatments ... a secondary focus on peripheral vascular disease ... ,, The collaborative preclinical research projects will ...
(Date:12/15/2009)... Dec. 15 On January 20th, 2010, ... for Medical Publication Professionals (ISMPP) will be held ... UK. More than 100 attendees are expected at ... publication professionals, editors, publishers, medical writers and medical ... publications and the impact of guidelines and regulations ...
(Date:12/14/2009)... 14 Vermillion, Inc. (Pink Sheets: ... William C. Wallen, Ph.D. Chief Scientific Officer, ... IDEXX Laboratories, will be joining its board ... plan. ,, "Bill brings more than ... diagnostics and biotechnology," said Gail Page, Vermillion ...
(Date:12/14/2009)... Dec. 14 Lionbridge (Nasdaq: ... signed a new, three-year master services agreement ... products and services that serve patients in ... will become the sole provider for translation ... regulatory, marketing, training, human resources, legal, and ...
Breaking Biology Technology:AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3
... all-time low their confidence in search engines is growing. ... relevance. , ,Today's consumers value relevance online and offline. ... Click here to read report) by IProspect indicated ... engines regularly and that more than half of users ...
... Theres a new high-tech networking event starting in ... venture capitalists, angel investors and others who live ... Orlady, Drew Fleck, Tobey Andropolis and Bob Pankratz ... a commercial business enterprise. Instead, the Hive is ...
... the brain. In the past few months, university biomedical researchers ... can combat neural disorders and help patients live normal lives. ... and getting closer to market, their attention to detail has ... movement ,One major effort at the UW is the ...
Other Biology Technology:Your customer is a search engine 2A new high-tech networking event buzzes in Appleton 2A new high-tech networking event buzzes in Appleton 3Mental research at UW-Madison could correct disabilities 2Mental research at UW-Madison could correct disabilities 3
(Date:12/15/2009)... organism, but there are currently few resources that ... tissues in this species. A newly released ... Cold Spring Harbor Laboratory Press fills this gap. ... for the preparation, enumeration, and microscopic examination of ... in the mouse. The laboratory manual is ...
(Date:12/14/2009)... as a clean-burning, renewable fuel that could help wean ... caused by ozone, compared with gasoline, especially in winter, ... , Ozone production from both gasoline and E85, ... percent ethanol, is greater in warm sunny weather than ... because heat and sunlight contribute to ozone formation. But ...
(Date:12/14/2009)... (INTA-CSIC) has shown that hydrogen cyanide, urea and other ... basic biological molecules can be obtained from the salt ... published in the journal Chemistry & Biodiversity , ... Earth. , "We have shown that when Prussian blue ... a substance that could have played a fundamental role ...
Breaking Biology News(10 mins):New source of classical techniques for blood-based studies in the laboratory mouse 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Prussian blue linked to the origin of life 2Novel polymer could improve protein based drugs 9631 1Novel polymer could improve protein based drugs 9631 2Novel polymer could improve protein based drugs 9631 3United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 54927 1United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 54927 2United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 54927 3Cell Therapeutics Inc Announces Institutional Investor Purchases 2430 Million of Preferred Stock and Warrants 13632 1Cell Therapeutics Inc Announces Institutional Investor Purchases 2430 Million of Preferred Stock and Warrants 13632 2Cell Therapeutics Inc Announces Institutional Investor Purchases 2430 Million of Preferred Stock and Warrants 13632 3
... gasoline, and coal. Researchers are describing key advances in ... in the 21st Century in the eighth and ninth ... series. Those fuels include "green gasoline," "designer hydrocarbons," "the ... power an energy-hungry world into the future. , ...
... professor Karen Warkentin, working at the Smithsonian Tropical Research ... at a very early developmental stage actively respond to ... 7, 2008 issue of the Journal of Experimental ... be critical to the frogs, long-term survival. , , Red-eyed ...
... recommended flu vaccine appear to be less likely to catch ... every year. , This is according to new research published ... Center. The study looked at children between 6 months (the ... in 2003-2004 and 2004-2005. The study found that, even though ...
Other Biology News:Fuels of the future may come from 'ice that burns,' water and sunshine 2Red-eyed treefrog embryos actively avoid asphyxiation inside their eggs 2Flu shot protects kids -- even during years with a bad vaccine match 2
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Biology Products: